@article{e0ab0f1cf5604307b8387ddd718ab6e5,
title = "Lesser-Known Aspects of Deep Brain Stimulation for Parkinson's Disease: Programming Sessions, Hardware Surgeries, Residential Care Admissions, and Deaths",
abstract = "Objective: The long-term treatment burden, duration of community living, and survival of patients with Parkinson's disease (PD) after deep brain stimulation (DBS) implantation are unclear. This study aims to determine the frequency of programming, repeat hardware surgeries (of the intracranial electrode, implantable pulse generator [IPG], and extension-cable), and the timings of residential care and death in patients with PD treated with DBS. Materials and Methods: In this cross-sectional, population-based study, individual-level data were collected from the Australian government covering a 15-year period (2002–2016) on 1849 patients with PD followed from DBS implantation. Results: The mean DBS implantation age was 62.6 years and mean follow-up 5.0 years. Mean annual programming rates were 6.9 in the first year and 2.8 in subsequent years. 51.4\% of patients required repeat hardware surgery. 11.3\% of patients had repeat intracranial electrode surgery (including an overall 1.1\% of patients who were completely explanted). 47.6\% of patients had repeat IPG/extension-cable surgery including for presumed battery depletion. 6.2\% of patients had early repeat IPG/extension-cable surgery (within one year of any previous such surgery). Thirty-day postoperative mortality was 0.3\% after initial DBS implantation and 0.6\% after any repeat hardware surgery. 25.3\% of patients were admitted into residential care and 17.4\% died. The median interval to residential care and death was 10.2 years and 11.4 years, respectively. Age more than 65 years was associated with fewer repeat hardware surgeries for presumed complications (any repeat surgery of electrodes, extension-cables, and early IPG surgery) and greater rates of residential care admission and death. Conclusions: Data from a large cohort of patients with PD treated with DBS found that the median life span after surgery is ten years. Repeat hardware surgery, including of the intracranial electrodes, is common. These findings support development of technologies to reduce therapy burden such as enhanced surgical navigation, hardware miniaturization, and improved battery efficiency.",
keywords = "Complications, deep brain stimulation, outcomes, Parkinson's disease, programming strategies",
author = "Xu, \{San San\} and Malpas, \{Charles B.\} and Bulluss, \{Kristian J.\} and McDermott, \{Hugh J.\} and Tomas Kalincik and Wesley Thevathasan",
note = "Funding Information: Source(s) of financial support: This work was supported by the Colonial Foundation, St Vincent's Hospital Research Endowment Fund, and the National Health and Medical Research Council (project grant \#1103238). The Bionics Institute acknowledges the support it receives from the Victorian Government through its operational infrastructure program. San San Xu is supported by the National Health and Medical Research Council (postgraduate scholarship \#GNT1133295). Tomas Kalincik is supported by the National Health and Medical Research Council and the Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne. Wesley Thevathasan is supported by Lions International and the National Health and Medical Research Council. Funding Information: Wesley Thevathasan, Kristian J. Bulluss, and Hugh J. McDermott are founders and hold shares and/or options in DBS Technologies Pty Ltd which plans to commercialize the use of neuronal signals to improve DBS. Wesley Thevathasan, Kristian J. Bulluss, and Hugh J. McDermott are named inventors on related patents, which are assigned to DBS Technologies. San San Xu holds options in DBS Technologies Pty Ltd. Wesley Thevathasan has received honoraria from Medtronic and Boston Scientific. Dr. Kalincik reports grants from NHMRC; grants from Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, during the conduct of the study; grants, personal fees, and nonfinancial support from Biogen; grants and personal fees from Roche; grants, personal fees and nonfinancial support from Sanofi Genzyme; grants, personal fees and nonfinancial support from Merck; grants, personal fees and nonfinancial support from Novartis; personal fees from WebMD Global; personal fees from Teva; personal fees from BioCSL; grants from Celgene; personal fees from BMS, outside the submitted work. Charles B. Malpas reports no competing interests. Conflict of Interest: Funding Information: Source(s) of financial support: This work was supported by the Colonial Foundation, St Vincent's Hospital Research Endowment Fund, and the National Health and Medical Research Council (project grant \#1103238). The Bionics Institute acknowledges the support it receives from the Victorian Government through its operational infrastructure program. San San Xu is supported by the National Health and Medical Research Council (postgraduate scholarship \#GNT1133295). Tomas Kalincik is supported by the National Health and Medical Research Council and the Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne. Wesley Thevathasan is supported by Lions International and the National Health and Medical Research Council.Conflict of Interest: Wesley Thevathasan, Kristian J. Bulluss, and Hugh J. McDermott are founders and hold shares and/or options in DBS Technologies Pty Ltd which plans to commercialize the use of neuronal signals to improve DBS. Wesley Thevathasan, Kristian J. Bulluss, and Hugh J. McDermott are named inventors on related patents, which are assigned to DBS Technologies. San San Xu holds options in DBS Technologies Pty Ltd. Wesley Thevathasan has received honoraria from Medtronic and Boston Scientific. Dr. Kalincik reports grants from NHMRC; grants from Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, during the conduct of the study; grants, personal fees and nonfinancial support from Biogen; grants and personal fees from Roche; grants, personal fees, and nonfinancial support from Sanofi Genzyme; grants, personal fees, and nonfinancial support from Merck; grants, personal fees, and nonfinancial support from Novartis; personal fees from WebMD Global; personal fees from Teva; personal fees from BioCSL; grants from Celgene; personal fees from BMS, outside the submitted work. Charles B. Malpas reports no competing interests. Publisher Copyright: {\textcopyright} 2022 International Neuromodulation Society",
year = "2022",
month = aug,
doi = "10.1111/ner.13466",
language = "English",
volume = "25",
pages = "836--845",
journal = "Neuromodulation",
issn = "1094-7159",
publisher = "Wiley-Blackwell",
number = "6",
}